The share issue may raise up to approximately SEK 21.5 million before transaction costs and an additional approximately SEK 9.0 million upon full exercise of the warrants.

Finance GMP production

The purpose of the share issue is to finance GMP production, regulatory preparations, and the execution of a planned clinical Phase I study for the company’s leading vaccine candidate Ab-01.12 against pneumococcus. A portion of the proceeds may also be used to strengthen development collaborations and broaden the pipeline.

The share issue is carried out as a directed issue to professional investors, of which approximately 40% of the capital stems from the strategic collaboration initiated with Gunnar Sachs and Mats Wahlström about two years ago.

“This is a crucial step for Abera – advancing our lead candidate into clinical development and becoming a clinical-stage company. I would like to thank shareholders and partners without whom we could not have reached this point. Over the past years, we have undertaken extensive preparations in a cost-effective manner, allowing us to now begin the next phase of the project and enter a new era for the company. Starting a Phase I trial brings us closer to a vaccine that could potentially save millions of lives and reshape the pneumococcal vaccine market, which today exceeds USD 8 billion annually. We are grateful for the support received so far and look forward to welcoming both existing and new shareholders on this journey,” says Maria Alriksson, CEO of Abera Bioscience.